Skip Navigation

 

CONFERENCES & MEETINGS


 

CONFERENCES & MEETINGS IN 2017

 

THE LIVER MEETING® 2017

American Association for the Study of Liver Diseases

Walter E. Washington Convention Center, Washington, DC

October 20-24, 2017

Sponsored by the American Association for the Study of Liver Diseases (AASLD), the Meeting has a focus on the science and clinical practice of hepatology, providing the latest information on hepatology research and patient care.  Hepatologists from around the world exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.

DRUG-INDUCED LIVER INJURY CONFERENCE

FDA/CDER-Critical Path Institute

The US Food and Drug Administration, Center for Drug Evaluation and Research (FDA/CDER) and Critical Path Institute (C-Path) co-sponsor an annual Drug-Induced Liver Injury Conference.  The program is endorsed by the National Institutes of Health, Drug-Induced Liver Injury Network (DILIN), American Association for the Study of Liver Diseases (AASLD), Hamner-UNC Institute for Drug Safety Sciences, and the Pharmaceutical Research and Manufacturers of America (PhRMA).  The academic-industry-government Conference provides a forum to discuss new findings and thinking about DILI, including presentation by experts in clinical hepatology, toxicology, and other scientific fields.  Presentations from these conferences can be found on the AASLD website.

 

2017 DILI CONFERENCE XVII

FDA/CDER-Critical Path Institute

Meeting Theme:  Asymmetry of Drug Safety and Efficacy in Clinical Trials with DILI -

Toward Quantitative Estimate of Net Benefit to Patients

College Park Marriott Hotel and Conference Center

June 6-7, 2017

Previous DILI Conference Summaries

 

 

CONFERENCE & MEETING SUMMARIES

 

LIVER INJURY FROM HERBAL AND DIETARY SUPPLEMENTS

NIH-AASLD Workshop

Lister Hill Auditorium, NIH Campus, Bethesda, MD

May 4-5, 2015

A National Institutes of Health Workshop co-sponsored by the American Association for the Study of Liver Diseases (AASLD), US Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and US Department of Agriculture (USDA).  The Workshop purpose is to evaluate the use of herbals and dietary supplements and the problem of their occasional hepatotoxicity.

 

CLINICAL ALERTS, NEWS, UPDATES

 

Top of page

 

 

PDF documents are best viewed with the free Adobe® Reader